Larvol Delta - GALAXIES-Lung301-A-Study-of-Belrestotug-Plus-Dostarlimab-Compared-With-Placebo-Plus-Pembrolizumab-in-Previously-Untreated-Participants-With-Programmed-Death-Ligand-1-PDL1-High-Nonsmallcell-Lung-Cancer-NSCLC

Jemperli (dostarlimab-gxly) - GSK

Keytruda (pembrolizumab) - Merck (MSD)

belrestotug (EOS-448) - GSK, Concentra Biosciences

http://clinicaltrials.gov/ct2/show/NCT06472076

Jun 17, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next